# A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

> **NCT07083505** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** HB1801
- **DRUG:** Taxotere®

## Key facts

- **NCT ID:** NCT07083505
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-10-11
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083505, "A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07083505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*